Annular alpha-synuclein oligomers are potentially toxic agents in alpha-synucleinopathy. Hypothesis

Neurotoxicity Research

Volumn 7, Issue 1-2, 2005, Pages 59-67

  Pountney, Dean L ^a   Voelcker, Nicolas H ^a   Gai, Wei Ping ^a  

^a FLINDERS UNIVERSITY   (Australia)

Author keywords

Synuclein; Amyloid; Atomic force microscopy; Multiple system atrophy; Neurodegeneration; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; NERVE PROTEIN; SNCA PROTEIN, HUMAN; SYNUCLEIN;

ANIMAL; CHEMISTRY; DEGENERATIVE DISEASE; GENETICS; HUMAN; METABOLISM; PATHOLOGY; REVIEW;

ALPHA-SYNUCLEIN; ANIMALS; HUMANS; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; SYNUCLEINS;

EID: 15844403848     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033776     Document Type: Article

References (62)

1. Bucciantini M, E Giannoni, F Chiti, F Baroni, L Formigli, J Zurdo, N Taddel, G Ramponi, C Dobson and M Stefani (2002) Inherent toxity of aggregates implies a common mechanism for protein misfolding diseases. Nature 416, 507-511.
2. Campbell BC, CA McLean, JG Culvenor, WP Gai, PC Blumbergs, P Jakala, K Beyreuther, CL Masters and QX Li (2001) Solubility of α-synuclein differs between multiple system atrophy and dementia with Lewy bodies. J. Neurochem. 76, 87-96.
3. Chartier-Harlin MC, J Kachergus, C Roumier, V Mouroux, X Douay, S Lincoln, C Levecque, L Larvor, J Andrieux, M Hulihan, N Waucquier, L Defebvre, P Amouyel, M Farrer and A Destee (2004) α-Synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364, 1167-1169.
4. Choi P, N Golts, H Snyder, M Chong, L Petrucelli, J Hardy, D Sparkman, E Cochran, JM Lee and B Wolozin (2001) Co-association f parkin and α-synuclein. Neuroreport 12, 2839-2843.
5. Conway K, J Harper and PT Lansbury (2000a) Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563.
6. Conway KA, S Lee, J Rochet, T Ding, R Williamson and P Lansbury Jr (2000b) Acceleration of oligomerization, not fibrillization, is a shared property of both α-synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. USA 99, 571-576.
7. Crocker S J, PD Smith, V Jackson-Lewis, WR Lamba, SP Hayley, E Grimm, SM Callaghan, RS Slack, E Melloni, S Przedborski, GS Robertson, H Anisman, Z Merali and DS Park (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson's disease. J. Neurosci. 23, 4081-4091.
8. Cuervo AM, L Stefanis, R Fredenburg, PT Lansbury and D Sulzer (2004) Impaired degradation of mutant C -synuclein by chaperone-mediated autophagy. Science 305, 1292-1295.
9. Davidson WS, A Jonas, DF Clayton and JM George (1998) Stabilization of ?-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273, 9443-9449.
10. Ding T, S Lee, J Rochet and PT Lansbury (2002) Annular α-synuclein protofibrils are produced when spherical protofibrils are incubated in solution or bound to brain derived membranes. Biochemistry 41, 10209-10217.
11. Eliezer D, E Kutluay, R Bussell and G Browne (2001) Conformational properties of α-synuclein in its free and lipidassociated states. J. Mol. Biol. 307, 10661-10673.
12. Fang Y, S Cheley, H Bayley and J Yang (1997) The heptameric prepore of a staphylococcal ?-hemolysin mutant in lipid bilayers imaged by atomic force microscopy. Biochemistry 36, 9518-9522.
13. Feany MB and WW Bender (2000) A Drosophila model of Parkinson's disease. Nature 404, 394-398.
14. Fernandez-Lopez S, H-S Kim, EC Choi, M M Delgado, JR Granja, A Khasanov, K Kraehenbuehl, G Long, DA Weinberger, KM Wilcox n and MR Ghadiri (2001) Antibacterial agents based on the cyclic D,L-α-peptide architecture. Nature 412, 452-455.
15. Fotiadis D, S Scheuring, SA Muller, A Engel and DJ Muller (2002) maging and manipulation of biological structures with the AFM. Micron 33, 385-397.
16. Gai WP, JHT Power, PC Blumbergs and WW Blessing (1998) Multiple system atrophy - a new α-synuclein disease? Lancet 352, 547-548.
17. Gai WP, JHT Power, PC Biumbergs, JG Culvenor and PH Jensen (1999) α-Synuclein immunoisolation of glial inclusions from multiple system atrophy brain tissue reveals multiprotein components. J. Neurochem. 73, 2093-2100.
18. Gai WP, HX Yuan, QX Li, JHT Power, PC Blumbergs and PH Jensen (2000) In situ and in vitro study of colocalization and segregation of α-synuclein, ubiquitin and lipids in cortical Lewy bodies. Exp. Neurol. 166, 324-333.
19. Gai WP, DL Pountney, JHT Power, QX Li, JG Culvenor, CA McLean, PH Jensen and PC Blumbergs (2003) α-Synuclein fibrils constitute the central core of oligodendroglial inclusion filaments in multiple system atrophy. Exp. Neurol. 181, 68-78.
20. Goedert M (2001) α-Synuclein and neurodegenerative diseases. Nat. Rev. Neurosci. 2, 492-501.
21. Goedert M and MG Spillantini (1998) Lewy body diseases and multiple system atrophy as α-synucleinopathies. Mol. Psychiatry 3, 462-465.
22. Hatters DM, CA MacRaild, R Daniels, WS Gosal, NH Thomson, JA Jones, JJ Davis, CE MacPhee, CM Dobson and GJ Howlett (2003) The circularization of amyloid fibrils formed by apolipoprotein C-II. Biophys. J. 85, 3979-3990.
23. Jensen PH and WP Gai (2001) α-Synuclein. Axonal transport, ligand interaction and neurodegeneration. Adv. Exp. Med. Biol.: Neuropath. Genet. Dementia 487, 129-134.
24. Jensen PH, K Islam, JM Kenney, MS Nielsen, J Power and WP Gai (2000) Microtubule-associated protein 1B is a component of cortical Lewy bodies and binds α-synuclein filaments. J. Biol. Chem. 275, 21500-21507.
25. Kahle PJ, M Neumann, L Ozmen, V Muller, H Jacobsen, W Spooren, B Fuss, B Mallon, WB Macklin, H Fujiwara, M Hasegawa, T Iwatsubo, HA Kretzschmar and C Haass (2002) Hyperphosphorylation and insolubility of α-synuclein in transgenic mouse oligodendrocytes. EMBO Rep. 3, 583-588.
26. Kanda S, JF Bishop, MA Eglitis, Y Yang and MM Mouradian (2000) Enhanced vulnerability to oxidative stress by C -synuclein mutations and C-terminal truncation. Neuroscience 97, 279-284.
27. Kitada T, S Asakawa, N Hattori, H Matsumine, Y Yamamura, S Minoshima, M Yokochi, Y Mizuno and N Shimizu (1998) Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608.
28. Kopito RR (2000) Aggresomes, inclusion bodies and protein aggregation. Trends Cell. Biol. 10, 524-530.
29. Kruger R, W Kuhn, T Muller, D Woitalla, M Graeber, S Kosel, H Przuntek, JT Epplen, L Schols and O Riess (1998) Ala30Pro mutation in the gene encoding α-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
30. Lashuel H, B Petre, J Wall, M Simon, R Nowak, T Walz and PT Lansbury (2002) α-Synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J. Mol. Biol. 322, 1089-1102.
31. Lee HJ and SJ Lee (2002) Characterization of cytoplasmic α-synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. J. Biol. Chem. 277, 48976-48983.
32. Li J, VN Uversky and AL Fink (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein. Biochemistry 40, 11604-11613.
33. Lindersson E, R Beedholm, P Højrup, T Moos, WP Gai, KB Hendil and PH Jensen (2004) Proteasomal inhibition by α-synuclein filaments and oligomers. J. Biol. Chem. 279, 12924-12934.
34. 2+ selectively induces α-synuclein annular oligomers via interaction with the C-terminal domain. Protein Sci. 13 (12), 3245-3252. Epub 2004 Nov 10.
35. 2+ -binding protein equine lysozyme: Formation of ring and linear structures depends on pH and metal ion concentration. J. Mol. Biol. 330, 879-890.
36. Martinez J, I Moeller, H Erdjument-Bromage, P Tempst and B Lauring (2003) Parkinson's disease-associated α-synuclein is a calmodulin substrate. J. Biol. Chem. 278, 17379-17387.
37. Masliah E, E Rockenstein, I Veinbergs, M Mallory, M Hashimoto, A Takeda, Y Sagara, A Sisk and L Mucke (2000) Dopaminergic loss and inclusion body formation in α-synuclein mice: Implications for neurodegenerative disorders. Science 287, 1265-1269.
38. McLean PJ, H Kawamata and BT Hyman (2001) α-Synucleinenhanced green fluorescent protein fusion proteins form proteasome sensitive inclusions in primary neurons. Neuroscience 104, 901-912.
39. McNaught KS, P Shashidharan, DP Perl, P Jenner and CW Olanow (2002) Aggresome-related biogenesis of Lewy bodies. Eur. J. Neurosci. 16, 2136-2148.
40. Mishizen-Eberz AJ, RP Guttmann, BI Giasson, GA Day III R Hodara, H Ischiropoulos, VM Lee, JQ Trojanowski and DR Lynch (2003) Distinct cleavage patterns of normal and pathologic forms of α-synuclein by calpain I in vitro. J. Neurochem. 86, 836-847.
41. 2+ binding to α-synuclein regulates ligand binding and oligomerization. J. Biol. Chem. 276, 22680-22684.
42. Outeiro TF and S Lindquist (2003) Yeast cells provide insight into α-synuclein biology and pathobiology. Science 302, 1772-1775.
43. Polymeropoulos MH, C Lavedan, E Leroy, SE Ide, A Dehejia,A Dutra, B Pike, H Root, J Rubenstein, R Boyer, ES Stenroos, S Chandrasekharappa, A Athanassiadou, T Papapetropoulos, WG Johnson, AM Lazzarini, RC Duvoisin, G Di Iorio, LI Golbe and RL Nussbaum (1997) Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
44. Pountney DL, R Lowe, M Quilty, JC Vickers, NH Voelcker and WP Gai (2004) Annular α-synuclein species from purified multiple system atrophy inclusions. J. Neurochem. 90, 502-512
45. Power JHT, J Shanon, PC Blumbergs and WP Gai (2002) Non-selenium glutathione peroxidase in human brain: Elevated level in Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol. 161, 885-894.
46. Quilty MC, WP Gai, DL Pountney, AK West and JC Vickers (2003) Localisation of α-, β- and γ-synuclein during neuronal development and alterations associated with the neuronal response to axonal trauma. Exp. Neurol. 182, 195-207.
47. Raab A, W Han, D Badt, SJ Smith-Gill, SM Lindsay, H Schindler and P Hinterdorfer (1999) Antibody recognition imaging by force microscopy. Nat. Biotech. 17, 902-905.
48. Schlossmacher MG, MP Frosch, WP Gai, M Medina, H Shimura, T Ochiishi, N Hattori, Y Mizuno, DJ Selkoe and KS Kosik (2002) Parkin and α-synuclein interact in normal brain and colocalize in Lewy bodies of Parkinson disease. Am. J. Pathol. 160, 1655-1667.
49. Shimura H, MG Schlossmacher, N Hattori, MP Frosch, A Trockenbacher, R Schneider, Y Mizuno, KS Kosik and DJ Selkoe (2001) Ubiquitination of a new form of ?-synuclein by parkin from human brain: Implications for Parkinson's disease. Science 293, 263-269.
50. Singleton AB, M Farrer, J Johnson, A Singleton, S Hague, J Kachergus, M Hulihan, T Peuralinna, A Dutra, R Nussbaum, S Lincoln, A Crawley, M Hanson, D Maraganore, C Adler, MR Cookson, M Muenter, M Baptista, D Miller, J Blancato, J Hardy and K Gwinn-Hardy (2003) α-Synuclein locus triplication causes Parkinson's disease. Science 302, 841.
51. Snyder H, K Mensah, C Theisler, J Lee, A Matouschek and B Wolozin (2003) Aggregated and monomeric α-synuclein bind to the S6' proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278, 11753-11759.
52. Song L, MR Hobaugh, C Shustak, S Cheley, H Bayley and JE Gouaux (1996) Structure of staphylococcal α-hemolysin, a heptameric transmembrane pore. Science 274, 1859-1866.
53. Souza JM, BI Giasson, Q Chen, VM Lee and H Ischiropoulos (2000) Dityrosine cross-linking promotes formation of stable α-synuclein polymers. Implication of nitrative and oxidative stress in the pathogenesis of neurodegenerative synucleinopathies. J. Biol. Chem. 275, 18344-18349.
54. Stefanova N, L Klimaschewski, W Poewe, GK Wenning and M Reindl (2001) Glial cell death induced by overexpression of α-synuclein. J. Neurosci. Res. 65, 432-438.
55. Tompkins MM, WP Gai, S Douglas and SJ Bunn (2003) α-Synuclein expression localizes to the Golgi apparatus in bovine adrenal medullary chromaffin cells. Brain Res. 984, 233-236.
56. Ueda K, H Fukushima, E Masliah, Y Xia, A Iwai, M Yoshimoto, DA Otero, J Kondo, Y Ihara and T Saitoh (1993) Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 11282-11286.
57. Uversky VN, J Li and AL Fink (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human α-synuclein. A possible molecular link between Parkinson's disease and heavy metal exposure. J. Biol. Chem. 276, 44284-44296.
58. Volles MJ and PT Lansbury Jr (2002) Vesicle permeabilization by protofibrillar α-synuclein is sensitive to Parkinson's diseaselinked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602.
59. Volles MJ and PT Lansbury Jr (2003) Zeroing in on the pathogenic form of ?-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42, 7871-7878.
60. Weinreb PH, W Zhen, AW Poon, KA Conway and PT Lansbury Jr (1996) NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry 35, 13709-13715.
61. Wenning GK, C Colosimo, F Geser and W Poewe (2004) Multiple system atrophy. Lancet Neurol. 3, 93-103.
62. Zarranz JJ, J Alegre, JC Gomez-Esteban, E Lezcano, R Ros, I Ampuero, L Vidal, J Hoenicka, O Rodriguez, B Atares, V Llorens, E Gomez Tortosa, Tdel Ser, DG Munoz and JG de Yebenes (2004) The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55, 164-173.